Described herein are compositions that are suitable for use in analyte sensing in biological samples and in medical diagnostics. The compositions include an oxidase capable of oxidizing the analyte of interest to produce hydrogen peroxide, a peroxidase, and a chemical compound, such as a near-infrared fluorescent compound, that is a substrate for the peroxidase. The oxidase, the peroxidase, and the chemical compound are encapsulated by vesicle that includes a lipid or polymeric bilayer, such as liposome and polymersome. The peroxidase catalyzes the oxidation of the chemical compound by hydrogen peroxide. Methods of analyte sensing in biological samples using these compositions, and methods of preparing the compositions are also described.

Described herein are compositions that are suitable for use in analyte sensing in biological samples and in medical diagnostics. The compositions include an oxidase capable of oxidizing the analyte of interest to produce hydrogen peroxide, a peroxidase, and a chemical compound, such as a near-infrared fluorescent compound, that is a substrate for the peroxidase. The oxidase, the peroxidase, and the chemical compound are encapsulated by vesicle that includes a lipid or polymeric bilayer, such as liposome and polymersome. The peroxidase catalyzes the oxidation of the chemical compound by hydrogen peroxide. Methods of analyte sensing in biological samples using these compositions, and methods of preparing the compositions are also described.

The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.

The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.

A biorelevant precursor composition suitable, upon dispersing, dilution or suspension in an aqueous medium, for simulating fed-state gastric fluids of mammalian species, wherein said biorelevant precursor composition comprises a substantially solid/sol-id-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion/concentrate, comprising at least one primary component selected from each of the following groups of primary components comprising: i) Triglyceride and/or diglyceride and/or monoglyceride or any combinations thereof in an amount of from 1-70% by weight; ii) Lecithin and/or lysolecithin in an amount of from 1-45% by weight; iii) Carbohydrate in an amount of from 15-70% by weight; and iv) Water or other aqueous medium in an amount of from 1-70% by weight; wherein the weight ratio of total fats (one or more primary components from each of groups i) and ii) combined): total carbohydrates (one or more primary components from group iii) combined) is between 20:1 to 1:20; and the weight ratio of glyceride:lecithin and/or lysolecithin is between 45:1 and 1:45; and in addition at least one additional component selected from at least one of the following: (i) fatty acids (between 0.01-15% by weight); (ii) bile acid/salt (between 0.01-3% by weight); (iii) enzymes (between 0.01-2% by weight); (iv) cholesterol, sterols (between 0.01-5% by weight); (v) buffer agents (between 0.01-4% by weight); (vi) osmotic agents (between 0.01-10% by weight); 52 (vii) proteins (collagen, protein hydrolysates, amino acids) (between 0.01-30% by weight); (viii) mucin (between 0.1-5% by weight); (ix) viscosity modifier (between 0.1-5% by weight); and (x) preservatives, stabilizers (between 0.01-3% by weight), such as a) anti-oxidants, b) chelating agents, c) buffers (inorganic or organic), and d) antimicrobials; all percentages being by dry weight. A method of producing these compositions is also provided.

A biorelevant precursor composition suitable, upon dispersing, dilution or suspension in an aqueous medium, for simulating fed-state gastric fluids of mammalian species, wherein said biorelevant precursor composition comprises a substantially solid/sol-id-like concentrate, a viscous gel-like concentrate, or a liquid fat dispersion/concentrate, comprising at least one primary component selected from each of the following groups of primary components comprising: i) Triglyceride and/or diglyceride and/or monoglyceride or any combinations thereof in an amount of from 1-70% by weight; ii) Lecithin and/or lysolecithin in an amount of from 1-45% by weight; iii) Carbohydrate in an amount of from 15-70% by weight; and iv) Water or other aqueous medium in an amount of from 1-70% by weight; wherein the weight ratio of total fats (one or more primary components from each of groups i) and ii) combined): total carbohydrates (one or more primary components from group iii) combined) is between 20:1 to 1:20; and the weight ratio of glyceride:lecithin and/or lysolecithin is between 45:1 and 1:45; and in addition at least one additional component selected from at least one of the following: (i) fatty acids (between 0.01-15% by weight); (ii) bile acid/salt (between 0.01-3% by weight); (iii) enzymes (between 0.01-2% by weight); (iv) cholesterol, sterols (between 0.01-5% by weight); (v) buffer agents (between 0.01-4% by weight); (vi) osmotic agents (between 0.01-10% by weight); 52 (vii) proteins (collagen, protein hydrolysates, amino acids) (between 0.01-30% by weight); (viii) mucin (between 0.1-5% by weight); (ix) viscosity modifier (between 0.1-5% by weight); and (x) preservatives, stabilizers (between 0.01-3% by weight), such as a) anti-oxidants, b) chelating agents, c) buffers (inorganic or organic), and d) antimicrobials; all percentages being by dry weight. A method of producing these compositions is also provided.

A fatty liver disease risk evaluation device can generate, through use of an estimation model generating unit, an estimation model for estimating the risk level of fatty liver disease by machine learning using attribute data such as sex and age, physical finding data such as height and weight, and doctor diagnostic results in addition to blood test data as an estimation model. In the fatty liver disease risk estimation device, a data acquisition unit acquires not only blood test data of a subject, but also attribute data such as sex and age, and physical finding data such as height and weight. In the fatty liver disease risk evaluation device, a risk level inference unit furthermore evaluates the risk of fatty liver disease based on the estimation model generated by the estimation model generating unit and the subject data acquired by the data acquisition unit.

This invention provides a method for quantification of lipoprotein cholesterol in two steps using an autoanalyzer without pretreatment of an analyte, wherein spontaneous color development of a reagent during storage is suppressed, a kit for quantification used in the method, and a method for preparing such kit. The kit for quantification of lipoprotein cholesterol in a sample obtained from a subject used in the method for quantification of lipoprotein cholesterol in two steps comprises: (1) a first reagent composition comprising cholesterol esterase, cholesterol oxidase, cholesterol esterase, and cholesterol oxidase and leading lipoprotein cholesterol other than the analyte to the outside of the reaction system; and (2) a second reagent composition for quantifying the analyte lipoprotein cholesterol, wherein either the first reagent composition or the second reagent composition comprises at least a coupler, an iron complex, peroxidase, catalase, a hydrogen donor, and a surfactant, provided that the coupler and the hydrogen donor are not allowed to be present in the same reagent composition, and the coupler, the iron complex, and peroxidase are not allowed to be present together in either of the first reagent composition or the second reagent composition.

This invention provides a method for quantification of lipoprotein cholesterol in two steps using an autoanalyzer without pretreatment of an analyte, wherein spontaneous color development of a reagent during storage is suppressed, a kit for quantification used in the method, and a method for preparing such kit. The kit for quantification of lipoprotein cholesterol in a sample obtained from a subject used in the method for quantification of lipoprotein cholesterol in two steps comprises: (1) a first reagent composition comprising cholesterol esterase, cholesterol oxidase, cholesterol esterase, and cholesterol oxidase and leading lipoprotein cholesterol other than the analyte to the outside of the reaction system; and (2) a second reagent composition for quantifying the analyte lipoprotein cholesterol, wherein either the first reagent composition or the second reagent composition comprises at least a coupler, an iron complex, peroxidase, catalase, a hydrogen donor, and a surfactant, provided that the coupler and the hydrogen donor are not allowed to be present in the same reagent composition, and the coupler, the iron complex, and peroxidase are not allowed to be present together in either of the first reagent composition or the second reagent composition.

The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint. Step iii) may be carried out at any stage up to and including step iv) but before steps v) or vi). The reagent of step iii) may be applied to the sample separately or may be included in a reagent mixture during steps i) or iv). A corresponding kit is also provided.